The China Mail - Moderna says US refusing to review mRNA-based flu shot

USD -
AED 3.672502
AFN 63.999758
ALL 81.109773
AMD 359.873322
ANG 1.789785
AOA 917.999983
ARS 1535.226207
AUD 1.422192
AWG 1.8025
AZN 1.696076
BAM 1.74477
BBD 2.011597
BDT 123.993042
BGN 1.747831
BHD 0.377091
BIF 2997.279094
BMD 1
BND 1.275971
BOB 12.110264
BRL 5.4401
BSD 0.998796
BTN 94.782997
BWP 13.79901
BYN 2.942058
BYR 19600
BZD 2.008653
CAD 1.396775
CDF 2314.99993
CHF 0.824605
CLF 0.025228
CLP 992.919725
CNY 6.661098
CNH 6.652785
COP 3164.280298
CRC 454.168339
CUC 1
CUP 23.969847
CVE 98.367456
CZK 21.82865
DJF 177.849146
DKK 6.697195
DOP 60.537937
DZD 135.196931
EGP 55.990178
ERN 15
ETB 161.241358
EUR 0.89607
FJD 2.243702
FKP 0.746726
GBP 0.746895
GEL 2.600101
GGP 0.746726
GHS 11.635666
GIP 0.746726
GMD 74.000279
GNF 8839.823364
GTQ 7.635488
GYD 209.349213
HKD 7.84413
HNL 26.845087
HRK 6.76901
HTG 130.853294
HUF 327.769503
IDR 18127.15
ILS 3.14456
IMP 0.746726
INR 94.912502
IQD 1514.072885
IRR 1868414.999723
ISK 121.830331
JEP 0.746726
JMD 158.713591
JOD 0.708975
JPY 157.768503
KES 129.791695
KGS 87.448703
KHR 4075.114858
KMF 441.000265
KPW 899.999961
KRW 1333.419749
KWD 0.31117
KYD 0.83233
KZT 452.856952
LAK 22487.176056
LBP 89438.155136
LKR 332.209287
LRD 169.784558
LSL 16.644543
LTL 2.95274
LVL 0.60489
LYD 6.420447
MAD 9.82042
MDL 17.877693
MGA 4517.596681
MKD 54.931085
MMK 2099.629361
MNT 3599.514763
MOP 8.070654
MRU 40.499576
MUR 47.280081
MVR 15.449684
MWK 1731.477764
MXN 18.787845
MYR 4.058203
MZN 63.91023
NAD 16.644543
NGN 1346.469726
NIO 36.754539
NOK 9.214898
NPR 151.652616
NZD 1.77723
OMR 0.382702
PAB 0.998885
PEN 3.456889
PGK 4.545252
PHP 63.764506
PKR 276.304474
PLN 3.95455
PYG 5851.286855
QAR 3.64084
RON 4.782198
RSD 104.839645
RUB 80.662951
RWF 1474.374415
SAR 3.7544
SBD 8.058206
SCR 14.652482
SDG 601.550744
SEK 9.817655
SGD 1.278315
SHP 0.748335
SLE 22.899359
SLL 20969.504398
SOS 570.765868
SRD 37.619497
STD 20697.981008
STN 21.856461
SVC 8.739016
SYP 13001.999685
SZL 16.639458
THB 33.723006
TJS 9.193541
TMT 3.5
TND 2.986752
TOP 2.40776
TRY 49.97125
TTD 6.771935
TWD 32.621397
TZS 2646.683617
UAH 45.299969
UGX 4244.613944
UYU 40.153441
UZS 11979.124849
VES 887.479795
VND 25803.5
VUV 118.626367
WST 2.776217
XAF 587.783136
XAG 0.02008
XAU 0.000256368843
XCD 2.70255
XCG 1.799991
XDR 0.707052
XOF 587.783136
XPF 106.3919
YER 236.198985
ZAR 16.70041
ZMK 9001.200902
ZMW 20.14006
ZWL 321.999592
SSP 5745.217636
MXV 2.117493
  • RYCEF

    0.4000

    19.71

    +2.03%

  • CMSC

    0.0000

    20.4

    0%

  • BTI

    0.4200

    56.05

    +0.75%

  • BP

    0.2800

    44.43

    +0.63%

  • RBGPF

    1.6000

    67

    +2.39%

  • RIO

    -0.1500

    94.41

    -0.16%

  • AZN

    -0.4300

    166.15

    -0.26%

  • GSK

    0.4600

    49.7

    +0.93%

  • BCE

    -0.4100

    20.56

    -1.99%

  • NGG

    -0.2500

    75.24

    -0.33%

  • VOD

    -0.0400

    16.58

    -0.24%

  • RELX

    -0.4500

    33.07

    -1.36%

  • BCC

    -0.5500

    76.59

    -0.72%

  • CMSD

    -0.0300

    20.27

    -0.15%

  • JRI

    -0.2500

    10.77

    -2.32%

Moderna says US refusing to review mRNA-based flu shot
Moderna says US refusing to review mRNA-based flu shot / Photo: © AFP

Moderna says US refusing to review mRNA-based flu shot

Vaccine manufacturer Moderna said Tuesday the US Food and Drug Administration was refusing to review an application for its first mRNA-based flu shot.

Text size:

The move comes as the current iteration of the FDA has called for a reconsideration of approval procedures for certain vaccines, including for influenza -- proposed federal policy changes under President Donald Trump that have triggered widespread alarm among public health and medical professionals.

Moderna, a US company, said the agency's top vaccine regulator, Vinay Prasad, wrote in a letter that Moderna's clinical trial was not "adequate and well-controlled," and had not tested its experimental shot against the best product on the market.

In the large trial Moderna had compared its new vaccine with Fluarix, an approved flu shot from the company GSK.

Moderna said the rejection was "inconsistent with previous written communications" with the FDA branch that regulates biological products, including vaccines, known by the acronym CBER.

The decision "did not identify any safety or efficacy concerns with our product" and "does not further our shared goal of enhancing America's leadership in developing innovative medicines," Moderna CEO Stephane Bancel said in the statement.

"It should not be controversial to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator in a study that was discussed and agreed on with CBER prior to starting."

Moderna said it had received a Refusal-to-File letter, which would indicate the application did not meet the requirements for substantive review. The company said it had requested a meeting to discuss the decision.

The letter did not identify any safety or efficacy concerns regarding the mRNA vaccine, said Moderna, which added the shot was accepted for review in the European Union, Canada and Australia.

During his first term Trump called mRNA technology a "modern-day miracle."

It was used during the Covid-19 pandemic to swiftly develop an immunization against the fast-spreading illness, and was credited with saving millions of lives.

Vaccines against Covid-19 are considered safe and effective by global health authorities, and protect against the most severe forms of the infection.

But in his second term, Trump has appointed Robert F. Kennedy Jr as his health chief, and the long-time vocal vaccine skeptic has spent the past year reshaping federal health agencies in his image.

That has meant spreading false information and sowing doubt about the safety and efficacy of vaccines widely known to be safe, and upending the pediatric immunization schedule.

Notably, Kennedy cut off federal research grants that funded mRNA development.

U.Chen--ThChM